<DOC>
	<DOCNO>NCT01390324</DOCNO>
	<brief_summary>The purpose study determine whether fixed-dose combination naratriptan + naproxen effective compare monotherapy acute treatment migraine .</brief_summary>
	<brief_title>Efficacy Safety Fixed-dose Combination Naratriptan Naproxen Acute Treatment Migraine</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Naratriptan</mesh_term>
	<criteria>Male female patient , age range 1865 year inclusive onset migraine age 50 ; Patient least 3month history migraine without aura accord ICHDII , 2004 , IHS ( International Headache Society ) criterion ; Patients experienced average migraine headache frequency 26 moderate severe attack per month last 03 month prior screen visit ; Patients able distinguish his/her migraine attack type headache ; Patients able understand consent participate clinical study , express signing Informed Consent ( IC ) . History 6 migraine attacks/month last 03 month prior screen visit ; History nonmigraine headache frequency ≥ 15 days/month 3 month prior screen . History follow migraine variant , accord ICHDII , 2004 , IHS ( International Headache Society ) : basilar migraine , aura without headache , familial hemiplegic migraine , sporadic hemiplegic migraine aura nonmigraine headache ; If female childbearing potential , negative urine pregnancy test Visit 0 us , agrees use , duration study , medically acceptable form contraception determine investigator ; Woman pregnancy lactation period ; History epilepsy psychiatric condition may affect compliance treatment ; Patients acupuncture treatment symptom migraine attack ; Suffers cardiovascular disease ( ischemic heart disease , include angina pectoris , myocardial infarction , document silent ischemia , Prinzmetal 's angina ) symptom ischemic heart disease ; History cerebrovascular pathology include stroke and/or transient ischemic attack ; History allergic reaction naproxen preparation , include subject aspirin NSAID drug induce syndrome asthma , rhinitis , nasal polyp urticaria ; Diagnosis renal hepatic failure ; Has significant ( determined investigator ) cardiovascular risk factor may include uncontrolled high blood pressure , postmenopausal woman , male 40 year old , hypercholesterolemia , obesity , diabetes mellitus , smoking , family history cardiovascular disease 1st degree relative . Patients stop change dosage preventive treatment migraine last 2 week prior screen visit ( V0 ) , include use calcium channel blocker , tricyclic antidepressant , beta blocker serotonergic medication indication ; Use prohibit medicine show 9.3 item protocol ; Inability understand report categorical scale debilitate functional study symptom diary ; Has abuse , opinion Investigator , follow drug , currently within past 2 year : opioids , alcohol , barbiturate , benzodiazepine , cocaine abuse drug migraine treatment include narcotic ergotamine headache past 03 month ; Hypersensitivity , intolerance , contraindication use naratriptan naproxen , component ; Hypersensitivity , intolerance , contraindication use sulfonamide ; History malignancy ≤ 5 year &gt; 5 year without documentation remission / cure , example , melanoma , leukemia , lymphoma , myeloproliferative disorder renal cell carcinoma duration . Exception : Subjects basal cell skin cancer , squamous cell , cervical cancer situ may eligible ; Participation last one year clinical protocol , unless direct benefit patient ; Any find clinical observation ( anamnesis physical exam ) laboratory abnormality ( eg , blood glucose , blood count ) , disease ( example , liver , cardiovascular system , lung ) therapy , opinion investigator , may endanger patient interfere endpoint study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Naratriptan</keyword>
	<keyword>Naproxen</keyword>
</DOC>